GoodRx Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were submitted during the Q&A session. Final voting results will be published in a Form 8-K filing.
-
Q1 saw strong revenue and EBITDA growth, led by Pharma Direct's 82% year-over-year increase and robust subscription momentum. Full-year guidance was raised, with Pharma Direct expected to grow over 50% and subscriptions scaling, despite ongoing pressure on prescription transactions revenue.
-
Shifts in insurance coverage and pharmacy closures are driving more consumers to seek cash savings and alternative prescription solutions. Growth is led by condition-based subscriptions and manufacturer partnerships, while a new Surescripts alliance aims to boost price transparency and adherence.
Fiscal Year 2025
-
Q4 and full-year 2025 results showed stable revenue and EBITDA growth, with Pharma Direct revenue up 41% year-over-year and new subscription offerings gaining traction. 2026 guidance reflects near-term revenue pressure from strategic investments, but long-term growth is expected as Pharma Direct and subscriptions scale.
-
Q3 2025 delivered solid results with $196M revenue and 54% growth in manufacturer solutions, offsetting a 9% decline in prescription transaction revenue. Strategic partnerships, new affordability programs, and a strong balance sheet position the company for long-term growth.
-
Q2 2025 revenue grew 1% year-over-year to $203.1M, with Pharma Manufacturer Solutions up 32%. Adjusted EBITDA margin improved to 34.2%. Guidance now includes $35–$40M revenue loss from Rite Aid and ISP headwinds, but full-year Adjusted EBITDA is expected to grow 2–6%.
-
Q1 2025 revenue grew 3% to $203M, with adjusted EBITDA up 11% and strong liquidity. Guidance for FY2025 remains $810–$840M revenue and $273–$287M adjusted EBITDA, with strategic focus on retail partnerships, manufacturer solutions, and e-commerce expansion.
-
A new CEO with deep industry experience is driving strategic growth through expanded brand partnerships, enhanced provider and retail relationships, and a shift to always-on manufacturer solutions. The company is leveraging industry trends and technology integration to position itself for continued revenue and EBITDA growth.
Fiscal Year 2024
-
Revenue grew 6% to $792.3M in 2024, with Adjusted EBITDA up 20% and margin expanding to 32.8%. 2025 guidance projects 4% revenue growth and 7% Adjusted EBITDA growth, driven by expanded brand partnerships and pharmacy collaborations.
-
Store closures and tougher pharmacy-PBM negotiations have created volatility, but a one-time reset is expected. Direct contracting and the Integrated Savings Program are driving growth and flexibility, while Pharma Manufacturer Solutions and point-of-sale discounts are expanding rapidly. EBITDA margins and free cash flow remain strong, with minimal impact from Medicare changes.
-
Management expects single-digit growth in 2025, with variability tied to PBM and pharmacy negotiations. Direct contracting now covers over 30% of volume, boosting margins, while Manufacturer Solutions and the Integrated Savings Program are expanding rapidly. Margin accretion is driven by operational efficiency and scalable programs.
-
Q3 revenue and adjusted EBITDA exceeded expectations, driven by strong Pharma Manufacturer Solutions growth, while retail pharmacy headwinds impacted the prescriptions marketplace. Guidance calls for continued double-digit growth in Manufacturer Solutions and margin expansion, with overall 2025 revenue growth expected in the single digits.
-
The session highlighted growth in direct contracting, cash pay pharma deals, and Manufacturer Solutions, with Kroger's return and expanded PBM partnerships driving future upside. Focus remains on high-value users, prescriber referrals, and leveraging marketing scale for competitive advantage.
-
Leadership has sharpened focus on retail partnerships, hybrid contracting, and scaling pharma solutions. Growth is driven by the Integrated Savings Program and manufacturer solutions, with strong margin expansion and disciplined capital allocation. The business is well-positioned amid pharmacy closures and evolving market dynamics.
-
Q2 2024 revenue grew 6% year-over-year to $200.6M, with adjusted EBITDA up 22% and margin expanding to 32.6%. Guidance for 2024 is at the lower end of the $800M–$810M range, with growth expected to accelerate in Q4, especially in pharma manufacturer solutions.